Case number 2017-2312
Dr. Falk Pharma GmbH v. GeneriCo, LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | DR. FALK PHARMA GMBH v. GENERICO, LLC [ORDER - NONPRECEDENTIAL] [nonprecedential] (0) |
| Apr 23, 2021 | 0 | DR. FALK PHARMA GMBH v. GENERICO, LLC [OPINION - NONPRECEDENTIAL] [nonprecedential] (0) |
| Apr 23, 2021 | 0 | DR. FALK PHARMA GMBH v. GENERICO, LLC [ERRATA] [nonprecedential] (0) |
| Jul 31, 2019 | 116 | Mandate issued to the United States Patent and Trademark Office. Service as of this date by the Clerk of Court. [624763] [JAB] [Entered: 07/31/2019 10:11 AM] (0) |
| Jul 11, 2019 | 115 | ERRATUM to the Nonprecedential Opinion Doc No.: [110]. Service as of this date by the Clerk of Court. [620271] [17-2312, 17-2636, 18-1320] [MJL] [Entered: 07/11/2019 10:43 AM] (0) |
| Jul 8, 2019 | 114 | ORDER filed granting motion to extend time to file petition for rehearing/en banc [113] filed by Appellant Dr. Falk Pharma GmbH in 17-2312, granting motion to extend time to file petition for rehearing/en banc [619063-2] filed by Appellants Dr. Falk Pharma GmbH and Salix Pharmaceuticals, Inc. in 17-2636. Petitions for Rehearing due on or before 07/24/2019. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [619411] [17-2312, 17-2636]--[Edited 07/08/2019 by JAB to correct pdf] [JAB] [Entered: 07/08/2019 10:21 AM] (0) |
| Jul 3, 2019 | 113 | MOTION of Appellant Dr. Falk Pharma GmbH to extend the time to file a Petiton or Panel Rehearing until 07/24/2019 [Consent: unopposed]. Service: 07/03/2019 by email. [619060] [17-2312] [Mary Bourke] [Entered: 07/03/2019 04:41 PM] (0) |
| Jun 26, 2019 | 112 | Bill of Costs for Appellee Mylan Pharmaceuticals Inc.. Service: 06/26/2019 by email. [617248] [17-2312] [Robert Florence] [Entered: 06/26/2019 08:35 PM] (0) |
| Jun 12, 2019 | 110 | OPINION filed for the court by Lourie, Circuit Judge; O'Malley, Circuit Judge and Reyna, Circuit Judge. Nonprecedential Opinion. [613429] [17-2312, 17-2636, 18-1320] [JAB] [Entered: 06/12/2019 10:23 AM] (0) |
| Jun 12, 2019 | 111 | JUDGMENT filed. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [613432] [JAB] [Entered: 06/12/2019 10:24 AM] (0) |
| Mar 4, 2019 | 109 | Submitted after ORAL ARGUMENT by Mary W. Bourke for Dr. Falk Pharma GmbH and Robert Florence for Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc. Panel: Judge: Lourie , Judge: O'Malley , Judge: Reyna. [590019] [JAB] [Entered: 03/04/2019 12:30 PM] (0) |
| Feb 20, 2019 | 108 | ORDER filed unsealing the precedential court order [101]. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [587320] [17-2312, 17-2636, 18-2097] [JAB] [Entered: 02/20/2019 09:22 AM] (0) |
| Feb 15, 2019 | 107 | Response to notice of oral argument from the Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc.. [586444] [17-2312] [Robert Florence] [Entered: 02/15/2019 02:22 PM] (0) |
| Feb 15, 2019 | 105 | Response to notice of oral argument from the Appellant Dr. Falk Pharma GmbH. [586285] [17-2312] [Mary Bourke] [Entered: 02/15/2019 10:57 AM] (3) |
| Feb 15, 2019 | 106 | RESPONSE of Appellant Dr. Falk Pharma GmbH and Intervenors Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. to the court order [102] , court order [102] , court order [102]. Service: 02/15/2019 by email. [586293] [17-2312] [Mary Bourke] [Entered: 02/15/2019 11:07 AM] (3) |
| Feb 11, 2019 | 104 | SEALED ERRATA to the court order Doc No.: [101]. Service as of this date by the Clerk of Court. [584666] [17-2312, 17-2636, 18-2097] [JAB] [Entered: 02/11/2019 09:36 AM] (0) |
| Feb 8, 2019 | 101 | SEALED PRECEDENTIAL ORDER filed granting motion to disqualify [67] in 17-2312, granting motion to disqualify [527163-2] filed by Appellant Salix Pharmaceuticals, Inc. in 17-2636, granting motion to disqualify [539907-2] filed by Appellees Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Inc. in 18-2097. By: Lourie, Circuit Judge; O'Malley, Circuit Judge; and Reyna, Circuit Judge. Service as of this date by the Clerk of Court. [584346] [17-2312, 17-2636, 18-2097]--[Edited 02/20/2019 by JAB to unseal document pursuant to court's order] [JAB] [Entered: 02/08/2019 09:29 AM] (20) |
| Feb 8, 2019 | 102 | ORDER filed to show cause. Joint response to the show cause order is due on or before 02/15/2019. Oral argument on the merits for the above-captioned cases is scheduled for Monday, March 4, 2019 at 10:00 a.m. in Courtroom 203. By: Per Curiam. Service as of this date by the Clerk of Court. [584380] [17-2312, 17-2636] [JAB] [Entered: 02/08/2019 10:22 AM] (0) |
| Feb 8, 2019 | 103 | NOTICE OF ORAL ARGUMENT. Panel: 1903D+. Case scheduled Mar 04, 2019 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to Notice of Oral Argument due: 02/15/2019. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. [584387] [JAB] [Entered: 02/08/2019 10:31 AM] (2) |
| Jan 16, 2019 | 95 | Amended Entry of appearance for Mary W. Bourke as principal counsel for Appellant Dr. Falk Pharma GmbH. Service: 01/16/2019 by email. [578766] [17-2312] [Mary Bourke] [Entered: 01/16/2019 07:17 PM] (2) |
| Jan 16, 2019 | 96 | Amended Entry of appearance for Mary W. Bourke as principal counsel for Intervenors Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc.. Service: 01/16/2019 by email. [578767] [17-2312] [Mary Bourke] [Entered: 01/16/2019 07:18 PM] (2) |
| Jan 16, 2019 | 97 | Amended Entry of appearance for Dana K. Severance as of counsel for Appellant Dr. Falk Pharma GmbH. Service: 01/16/2019 by email. [578768] [17-2312] [Dana Severance] [Entered: 01/16/2019 07:21 PM] (2) |
| Jan 16, 2019 | 98 | Amended Entry of appearance for Dana K. Severance as of counsel for Intervenors Valeant Pharmaceuticals International, Inc. and Salix Pharmaceuticals, Inc.. Service: 01/16/2019 by email. [578769] [17-2312] [Dana Severance] [Entered: 01/16/2019 07:28 PM] (2) |
| Jan 16, 2019 | 99 | Amended Entry of appearance for Kristen Healey Cramer as of counsel for Appellant Dr. Falk Pharma GmbH. Service: 01/16/2019 by email. [578770] [17-2312] [Kristen Cramer] [Entered: 01/16/2019 07:30 PM] (2) |
| Jan 16, 2019 | 100 | Amended Entry of appearance for Kristen Healey Cramer as of counsel for Intervenors Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc.. Service: 01/16/2019 by email. [578772] [17-2312] [Kristen Cramer] [Entered: 01/16/2019 07:31 PM] (2) |
| Sep 12, 2018 | 93 | Submitted after ORAL ARGUMENT by Mary W. Bourke for Dr. Falk Pharma GmbH and Michael Isidoro Verde for Mylan Pharmaceuticals Inc. Panel: Judge: Lourie , Judge: O'Malley , Judge: Reyna. [549098] [JAB] [Entered: 09/12/2018 10:43 AM] (0) |
| Sep 12, 2018 | 94 | ORDER filed granting motion for leave to intervene for limited purpose [66] filed by Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [549181] [SJ] [Entered: 09/12/2018 01:24 PM] (2) |
| Sep 7, 2018 | 92 | Entry of appearance for Jonathan Rotenberg as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 09/07/2018 by email. [547918] [17-2312] [Jonathan Rotenberg] [Entered: 09/07/2018 11:31 AM] (2) |
| Aug 17, 2018 | 90 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [89], ERROR: Appellee Mylan Pharmaceuticals Inc. submitted a response to the oral argument order designating Michael I. Verde as arguing attorney. CORRECTION: The attorney is not in compliance with FCR 47.3. An Entry of Appearance must be filed on behalf of the arguing attorney. [543599] [JAB] [Entered: 08/17/2018 09:01 AM] (0) |
| Aug 17, 2018 | 91 | Entry of appearance for Michael I. Verde as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 08/17/2018 by email. [543795] [17-2312] [Michael Verde] [Entered: 08/17/2018 03:18 PM] (2) |
| Aug 15, 2018 | 88 | Response to oral argument order from the Appellant Dr. Falk Pharma GmbH. Designating Mary W. Bourke on behalf of Movants/Intervenors Salix and VPI to argue.. Designating 5 minutes for argument. [17-2312] [Mary Bourke] [Entered: 08/15/2018 11:24 AM] (0) |
| Aug 15, 2018 | 89 | Response to oral argument order from the Appellee Mylan Pharmaceuticals Inc.. Designating Michael I. Verde to argue.. Designating 30 minutes for argument. Reserving 0 minutes for rebuttal. [17-2312] [Michael Verde] [Entered: 08/15/2018 12:59 PM] (0) |
| Jul 26, 2018 | 86 | ORDER filed scheduling oral argument on the pending motions to disqualify and intervene for Wednesday, September 12, 2018 at 10:00 a.m. in Courtroom 201. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [538758] [17-2312, 17-2636, 18-2097] [JAB] [Entered: 07/26/2018 01:32 PM] (3) |
| Jul 26, 2018 | 87 | NOTICE OF CALENDARING. Panel: 1809J. Cases scheduled Sep 12, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 201. Response to oral argument order due: 08/15/2018. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [538760] THIS NOTICE APPLIES TO CASE(S): [17-2312, 17-2636, 18-2097] [JAB] [Entered: 07/26/2018 01:37 PM] (0) |
| Jul 24, 2018 | 85 | Notice from Appellant Dr. Falk Pharma GmbH from Intervenors Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. regarding conflicts with oral argument (Parties jointly submit this notice to advise the Court that all parties are available for oral argument on the following dates: no availability in Aug.; parties are available Sept.6,7,12-14; and available Oct. 22, 29-31, 2018). Service: 07/24/2018 by email. [538252] [17-2312] [Mary Bourke] [Entered: 07/24/2018 04:05 PM] (6) |
| Jul 17, 2018 | 84 | ORDER filed staying briefing on the merits in appeal 18-2097; response to [534203-2] confidential document, [534202-2] motion to disqualify due 07/19/2018 in appeal 18-2097; counsel must notify the court of argument conflicts for the entire months of August, September, and October. [see order for details]. By: (Per Curiam). Service as of this date by the Clerk of Court. [536450] [17-2312, 17-2636, 18-2097] [SJ] [Entered: 07/17/2018 11:36 AM] (5) |
| Jul 9, 2018 | 83 | ORDER filed granting motion to reschedule argument [78] filed by Appellee Mylan Pharmaceuticals Inc. in 17-2312, granting motion to reschedule argument [533172-2] filed by Appellees Mylan Pharmaceuticals Inc. and Mylan, Inc. in 17-2636. Oral argument will be rescheduled for a later date. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [534550] [17-2312, 17-2636] [JAB] [Entered: 07/09/2018 04:16 PM] (2) |
| Jul 5, 2018 | 81 | Letter from Appellee Mylan Pharmaceuticals Inc. In response to the Court's inquiry, I am pleased to report that we are available to argue the pending motions to disqualify and motion to intervene on August 6, 2018 at 2:00 p.m.. Service: 07/05/2018 by email. [533755] [17-2312] [Deepro Mukerjee] [Entered: 07/05/2018 12:50 PM] (1) |
| Jul 5, 2018 | 82 | Letter from Salix Pharmaceuticals, Inc. Valeant Pharmaceuticals International, Inc. Response to Clerk's Note to File regarding availability for oral argument on August 6, 2018. Service: 07/05/2018 by email. [533886] [17-2312] [Mary Bourke] [Entered: 07/05/2018 04:19 PM] (3) |
| Jul 3, 2018 | 80 | Clerk's Note to the File: By close of business on 07/05/2018, the parties shall submit letters regarding their availability to hold oral argument on the motions to disqualify and motion to intervene on August 6, 2018 at 2:00 pm. [533447] [17-2312, 17-2636] [JAB] [Entered: 07/03/2018 12:38 PM] (0) |
| Jul 2, 2018 | 78 | MOTION of Appellee Mylan Pharmaceuticals Inc. to reschedule argument [Consent: unopposed]. Service: 07/02/2018 by email. [533170] [17-2312] [Deepro Mukerjee] [Entered: 07/02/2018 03:24 PM] (18) |
| Jul 2, 2018 | 79 | Letter from Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. regarding Notice of Case Related to Motion to Disqualify. Service: 07/02/2018 by email. [533232] [17-2312] [Mary Bourke] [Entered: 07/02/2018 05:17 PM] (3) |
| Jun 28, 2018 | 77 | ORDER filed. Oral argument on the merits is postponed. Oral argument on the motions will proceed as scheduled. (see order for details) By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [532427] [17-2312, 17-2636] [SJ] [Entered: 06/28/2018 09:31 AM] (3) |
| Jun 26, 2018 | 75 | REPLY of Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. to response filed by Appellee, Doc. No [73], response filed by Appellee, Doc. No [72]. Service: 06/25/2018 by email. [532137] [17-2312] [Mary Bourke] [Entered: 06/26/2018 11:09 PM] (38) |
| Jun 26, 2018 | 76 | Sealed or confidential document received [Confidential Intervenors' Reply to Response to Motions to Intervene and Disqualify Katten Muchin Rosenman LLP as Counsel for Mylan Pharmaceuticals Inc.] (corresponding to Doc No. [75]) for. Service: 06/26/2018 by email. [532138] [17-2312] [Mary Bourke] [Entered: 06/26/2018 11:13 PM] (0) |
| Jun 19, 2018 | 74 | ORDER filed permitting a reply to [73] [72] responses. Reply due 06/26/2018. By: (Per Curiam). Service as of this date by the Clerk of Court. [530579] [SJ] [Entered: 06/19/2018 01:47 PM] (2) |
| Jun 15, 2018 | 68 | Response to oral argument order from the Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc.. Designating Robert L. Florence to argue.. Designating 12 minutes for argument. Reserving 3 minutes for rebuttal. [17-2312] [Robert Florence] [Entered: 06/15/2018 12:49 PM] (0) |
| Jun 15, 2018 | 69 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re:calendar response Docket No. [68], ERROR: Counsel for Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc. submitted a response to the oral argument order designating 12 minutes for argument and 3 minutes for rebuttal. The Oral Argument Order issued with the Notice of Calendaring states that appellees may not divide argument time. CORRECTION: Please promptly submit a corrected response. [529858] [JAB] [Entered: 06/15/2018 01:30 PM] (0) |
| Jun 15, 2018 | 70 | Response to oral argument order from the Appellant Dr. Falk Pharma GmbH. Designating Mary W. Bourke to argue.. Designating 12 minutes for argument. Reserving 3 minutes for rebuttal. [17-2312] [Mary Bourke] [Entered: 06/15/2018 01:37 PM] (0) |
| Jun 15, 2018 | 71 | CORRECTED Response to oral argument order from the Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc.. Designating Robert L. Florence to argue.. Designating 15 minutes for argument. [17-2312] [Robert Florence] [Entered: 06/15/2018 01:41 PM] (0) |
| Jun 15, 2018 | 72 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the motion [67]. Service: 06/15/2018 by email. [530045] [17-2312] [Deepro Mukerjee] [Entered: 06/15/2018 05:49 PM] (56) |
| Jun 15, 2018 | 73 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the motion [66]. Service: 06/15/2018 by email. [530047] [17-2312] [Deepro Mukerjee] [Entered: 06/15/2018 05:55 PM] (19) |
| Jun 5, 2018 | 63 | Entry of appearance for Mary W. Bourke as principal counsel for Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc.. Service: 06/05/2018 by email. [527166] [17-2312] [Mary Bourke] [Entered: 06/05/2018 10:47 PM] (2) |
| Jun 5, 2018 | 64 | Entry of appearance for Kristen Healey Cramer as of counsel for Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc.. Service: 06/05/2018 by email. [527167] [17-2312] [Mary Bourke] [Entered: 06/05/2018 10:49 PM] (2) |
| Jun 5, 2018 | 65 | Entry of appearance for Dana K. Severance as of counsel for Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc.. Service: 06/05/2018 by email. [527168] [17-2312] [Mary Bourke] [Entered: 06/05/2018 10:51 PM] (2) |
| Jun 5, 2018 | 66 | MOTION of Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. for leave to intervene [Consent: partial consent]. Service: 06/05/2018 by email. [527169] [17-2312] [Mary Bourke] [Entered: 06/05/2018 10:55 PM] (22) |
| Jun 5, 2018 | 67 | MOTION of Salix Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, Inc. to disqualify Katten Muchin Rosenman LLP as Counsel for Mylan Pharmaceuticals Inc.. [Consent: partial consent]. Service: 06/05/2018 by email. [527170] [17-2312] [Mary Bourke] [Entered: 06/05/2018 10:58 PM] (174) |
| May 21, 2018 | 62 | NOTICE OF CALENDARING. Panel: 1807I. Case scheduled Jul 13, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 201. Response to oral argument order due: 06/15/2018. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [523275] [JAB] [Entered: 05/21/2018 02:38 PM] (0) |
| Mar 12, 2018 | 60 | Notice from Appellant Dr. Falk Pharma GmbH regarding conflicts with oral argument (May 1-4, 2018 and June 7-8, 2018). Service: 03/12/2018 by email. [504372] [Mary Bourke] [Entered: 03/12/2018 05:15 PM] (3) |
| Mar 12, 2018 | 61 | Notice from Appellee Mylan Pharmaceuticals Inc. regarding conflicts with oral argument (April 30, 2018-May 4, 2018). Service: 03/12/2018 by email. [504402] [Robert Florence] [Entered: 03/12/2018 08:05 PM] (3) |
| Mar 6, 2018 | 59 | 6 paper copies of the Joint Appendix [57] received from Appellant Dr. Falk Pharma GmbH. [503213] [JCP] [Entered: 03/07/2018 01:04 PM] (0) |
| Mar 5, 2018 | 58 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks [MAY, JUN, JUL], or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 03/12/2018. [502588] [MJL] [Entered: 03/05/2018 02:57 PM] (0) |
| Mar 1, 2018 | 54 | TENDERED from Appellant Dr. Falk Pharma GmbH. Title: JOINT APPENDIX. Service: 03/01/2018 by email. [502075] [Mary Bourke] [Entered: 03/01/2018 02:25 PM] (441) |
| Mar 1, 2018 | 55 | Statement of Compliance with Fed. Cir. R. 33 for Appellant Dr. Falk Pharma GmbH and Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc.. Service: 03/01/2018 by email. [502076] [Mary Bourke] [Entered: 03/01/2018 02:27 PM] (5) |
| Mar 1, 2018 | 56 | Certificate of Compliance with Fed. Cir. R. 17 (Agency) for Appellant Dr. Falk Pharma GmbH and Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc.. Service: 03/01/2018 by email. [502080] [Mary Bourke] [Entered: 03/01/2018 02:29 PM] (5) |
| Mar 1, 2018 | 57 | APPENDIX FILED for Dr. Falk Pharma GmbH [54]. Number of Pages: 441. Service: 03/01/2018 by email. The paper copies of the appendix should be received by the court on or before 03/08/2018. [502168] [MJL] [Entered: 03/01/2018 04:21 PM] (441) |
| Feb 27, 2018 | 49 | 6 paper copies of the Reply Brief [48] received from Appellant Dr. Falk Pharma GmbH. [501411] [JCP] [Entered: 02/27/2018 01:52 PM] (0) |
| Feb 27, 2018 | 50 | Amended Entry of appearance for Robert L. Florence as principal counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 02/27/2018 by email. [501501] [Robert Florence] [Entered: 02/27/2018 03:54 PM] (2) |
| Feb 27, 2018 | 51 | Amended Entry of appearance for Micheal L. Binns as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 02/27/2018 by email. [501508] [Micheal Binns] [Entered: 02/27/2018 04:00 PM] (2) |
| Feb 27, 2018 | 52 | Amended Entry of appearance for Karen L. Carroll as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 02/27/2018 by email. [501513] [Karen Carroll] [Entered: 02/27/2018 04:06 PM] (2) |
| Feb 27, 2018 | 53 | Amended Entry of appearance for Sharad K. Bijanki as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 02/27/2018 by email. [501516] [Sharad Bijanki] [Entered: 02/27/2018 04:09 PM] (2) |
| Feb 22, 2018 | 47 | TENDERED from Appellant Dr. Falk Pharma GmbH. Title: REPLY BRIEF. Service: 02/22/2018 by email. [500515] [Mary Bourke] [Entered: 02/22/2018 11:34 PM] (38) |
| Feb 22, 2018 | 48 | REPLY BRIEF FILED for Appellant Dr. Falk Pharma GmbH [47]. Number of Pages: 29. Service: 02/22/2018 by email. The paper copies of the brief should be received by the court on or before 03/05/2018. Appendix is due 03/01/2018. [500904] [MJL] [Entered: 02/26/2018 08:55 AM] (38) |
| Feb 2, 2018 | 46 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [45] filed by Appellant Dr. Falk Pharma GmbH. The reply brief is due 02/22/2018. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [494603] [MJL] [Entered: 02/02/2018 08:30 AM] (0) |
| Feb 1, 2018 | 45 | MOTION of Appellant Dr. Falk Pharma GmbH to extend the time to 02/22/2018 at 11:59 pm to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 02/01/2018 by email. [494565] [Mary Bourke] [Entered: 02/01/2018 05:36 PM] (7) |
| Jan 29, 2018 | 44 | 6 paper copies of the Opening Response Brief [43] received from Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc. [493349] [CFT] [Entered: 01/29/2018 12:35 PM] (0) |
| Jan 25, 2018 | 42 | TENDERED from Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc.. Title: RESPONSE BRIEF. Service: 01/25/2018 by email. [492906] [Robert Florence] [Entered: 01/25/2018 10:05 PM] (70) |
| Jan 25, 2018 | 43 | BRIEF FILED for Appellees Flat Line Capital LLC, GeneriCo, LLC and Mylan Pharmaceuticals Inc. [42]. Number of Pages: 57. Service: 01/25/2018 by email. The paper copies of the brief should be received by the court on or before 02/02/2018. Appellant Dr. Falk Pharma GmbH's reply brief is due 02/08/2018. [492927] [MJL] [Entered: 01/26/2018 08:43 AM] (70) |
| Dec 21, 2017 | 41 | ORDER filed. The motion [482215-2] is granted to the extent that the amended notice of appeal in 2017-2636 filed with the United States District Court for the Northern District of West Virginia on December 11, 2017 shall be docketed as a new appeal and consolidated with 2017-2636. 2017-2636 and the new appeal shall remain companion cases with 2017-2312. Dr. Falk Pharma GmbH and Salix Pharmaceuticals, Inc. shall file a corrected opening brief including information concerning the new appeal no later than 7 days after the docketing of the new appeal. Service: 12/21/2017 by clerk. [484699] [17-2636, 17-2312] [LMS] [Entered: 12/21/2017 11:33 AM] (2) |
| Nov 27, 2017 | 40 | 6 paper copies of the Opening Brief [39] received from Appellant Dr. Falk Pharma GmbH. [478254] [CW] [Entered: 11/27/2017 02:59 PM] (0) |
| Nov 21, 2017 | 38 | TENDERED from Appellant Dr. Falk Pharma GmbH. Title: OPENING BRIEF. Service: 11/21/2017 by email. [477641] [Mary Bourke] [Entered: 11/21/2017 11:23 PM] (149) |
| Nov 21, 2017 | 39 | BRIEF FILED for Appellant Dr. Falk Pharma GmbH [38]. Number of Pages: 55. Service: 11/21/2017 by email. The paper copies of the brief should be received by the court on or before 12/01/2017. [477941] [MJL] [Entered: 11/22/2017 03:15 PM] (149) |
| Nov 7, 2017 | 37 | ORDER filed. Appeal No. 2017-2312 and Appeal No. 2017-2636 shall be considered companion cases and assigned to the same merits panel. Service: 11/07/2017 by clerk. [473826] [17-2312, 17-2636] [NL] [Entered: 11/07/2017 03:45 PM] (2) |
| Nov 2, 2017 | 36 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: The contact information included on the entries of appearance for Kristen Healey Cramer [34] and Dana K. Severance [35] does not match the information in the attorneys' user accounts. CORRECTION: Pursuant to FCR 47.3(c)(1), please update as needed to ensure the contact information on the entries of appearance and in the user accounts matches. [472501] [MJL] [Entered: 11/02/2017 01:58 PM] (0) |
| Nov 1, 2017 | 33 | Amended Entry of appearance for Mary W. Bourke as principal counsel for Appellant Dr. Falk Pharma GmbH. Service: 11/01/2017 by email. [472312] [Mary Bourke] [Entered: 11/01/2017 02:46 PM] (2) |
| Nov 1, 2017 | 34 | Amended Entry of appearance for Kristen Healey Cramer as of counsel for Appellant Dr. Falk Pharma GmbH. Service: 11/01/2017 by email. [472315] [Kristen Cramer] [Entered: 11/01/2017 02:49 PM] (2) |
| Nov 1, 2017 | 35 | Amended Entry of appearance for Dana K. Severance as of counsel for Appellant Dr. Falk Pharma GmbH. Service: 11/01/2017 by email. [472317] [Dana Severance] [Entered: 11/01/2017 02:52 PM] (2) |
| Oct 23, 2017 | 26 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: A portion of the motion [25] was submitted in an editable format. CORRECTION: Pursuant to FCR 25(c)(1)(K) and 25(d), all documents must be flattened. Please ensure future filings are not editable. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [469642] [MJL] [Entered: 10/23/2017 08:36 AM] (0) |
| Oct 23, 2017 | 27 | REMINDER: All counsel of record are reminded of their responsibility per FCR 47.3(c)(1) and FCR 47.4 to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. The court notes that the COIs included in the motion [25] do not match the COIs currently docketed in this appeal (item #5 has now been included). Please file amended COIs promptly. [469644] [MJL] [Entered: 10/23/2017 08:39 AM] (0) |
| Oct 23, 2017 | 28 | Certificate of Interest for the Appellee Mylan Pharmaceuticals Inc.. Service: 10/23/2017 by email. [469716] [Robert Florence] [Entered: 10/23/2017 10:15 AM] (3) |
| Oct 23, 2017 | 29 | Certificate of Interest for the Appellees Flat Line Capital LLC and GeneriCo, LLC. Service: 10/23/2017 by email. [469723] [Zachary Silbersher] [Entered: 10/23/2017 10:24 AM] (2) |
| Oct 23, 2017 | 30 | ORDER granting motion to extend time to file appellant's opening brief and appellees' response brief [25] filed by Appellant Dr. Falk Pharma GmbH. Appellant's brief is due 11/21/2017. Appellees' brief is due 01/25/2018. Service as of this date by Clerk of Court. [469735] [MJL] [Entered: 10/23/2017 10:44 AM] (2) |
| Oct 23, 2017 | 31 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Appellant's motion [25] selected an incorrect relief ("extend time to file (other)"). CORRECTION: When requesting an extension of time for an appellee's response brief, the correct relief is "extend time to file appellee/respondent/cross-appellant principal brief." Please ensure future motions select the correct relief(s). THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [469737] [MJL] [Entered: 10/23/2017 10:49 AM] (0) |
| Oct 23, 2017 | 32 | Certificate of Interest for the Appellant Dr. Falk Pharma GmbH. Service: 10/23/2017 by email. [469753] [Mary Bourke] [Entered: 10/23/2017 11:11 AM] (4) |
| Oct 20, 2017 | 25 | MOTION of Appellant Dr. Falk Pharma GmbH to extend the time to 11/21/2017 at 11:59 pm to file the appellant/petitioner's principal brief. Any response is due within 10 days of service, to extend time until 01/25/2018 at 11:59 pm to file (Appellees' responsive brief). [Consent: unopposed]. Service: 10/20/2017 by email. [469610] [Mary Bourke] [Entered: 10/20/2017 08:58 PM] (17) |
| Aug 28, 2017 | 24 | Certified list from the United States Patent and Trademark Office. Service: 08/28/2017 by email. Appellant's brief is due 10/27/2017. [457090] [CAB] [Entered: 08/28/2017 02:25 PM] (77) |
| Aug 23, 2017 | 23 | Official caption revised to reflect non-participation of Foxhill Capital Partners and Myconovo, Inc. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [455979] [MJL] [Entered: 08/23/2017 08:43 AM] (0) |
| Aug 16, 2017 | 22 | Second notice to counsel for Appellees Foxhill Capital Partners and Myconovo, Inc.: The record of this case indicates that no Entry of Appearance, Certificate of Interest, or Docketing Statement has been filed. Please file these documents promptly. Service as of this date by Clerk of Court. [454257] [MJL] [Entered: 08/16/2017 09:27 AM] (0) |
| Aug 8, 2017 | 21 | Notice to counsel for Appellees Foxhill Capital Partners and Myconovo, Inc.: The record of this case indicates that no Entry of Appearance or Certificate of Interest has been filed. Please file these documents promptly. Service as of this date by Clerk of Court. [452053] [MJL] [Entered: 08/08/2017 10:39 AM] (0) |
| Aug 2, 2017 | 19 | NOTICE OF DEFICIENCY: The docketing statement [18] filed by Appellees GeneriCo, LLC and Flat Line Capital LLC in 17-2312 is incomplete and therefore cannot be accepted for filing at this time. Multiple boxes were left unchecked. You are being afforded the opportunity to correct the deficiency. Please ensure all appropriate boxes are checked and all items are properly filled out. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [450802] [MJL] [Entered: 08/02/2017 08:28 AM] (0) |
| Aug 2, 2017 | 20 | Amended Docketing Statement for the Appellees Flat Line Capital LLC and GeneriCo, LLC. Service: 08/02/2017 by email. [450818] [Zachary Silbersher] [Entered: 08/02/2017 09:23 AM] (3) |
| Aug 1, 2017 | 2 | Entry of appearance for Mary W. Bourke as principal counsel for Appellant Dr. Falk Pharma GmbH. Service: 08/01/2017 by email. [450722] [Mary Bourke] [Entered: 08/01/2017 03:37 PM] (2) |
| Aug 1, 2017 | 3 | Entry of appearance for Kristen Healey Cramer as of counsel for Appellant Dr. Falk Pharma GmbH. Service: 08/01/2017 by email. [450723] [Kristen Cramer] [Entered: 08/01/2017 03:39 PM] (2) |
| Aug 1, 2017 | 4 | Entry of appearance for Dana K. Severance as of counsel for Appellant Dr. Falk Pharma GmbH. Service: 08/01/2017 by email. [450725] [Dana Severance] [Entered: 08/01/2017 03:42 PM] (2) |
| Aug 1, 2017 | 5 | Certificate of Interest for the Appellant Dr. Falk Pharma GmbH. Service: 08/01/2017 by email. [450731] [Mary Bourke] [Entered: 08/01/2017 03:49 PM] (3) |
| Aug 1, 2017 | 6 | Docketing Statement for the Appellant Dr. Falk Pharma GmbH. Service: 08/01/2017 by email. [450732] [Mary Bourke] [Entered: 08/01/2017 03:50 PM] (4) |
| Aug 1, 2017 | 7 | Entry of appearance for Robert L. Florence as principal counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 08/01/2017 by email. [450750] [Robert Florence] [Entered: 08/01/2017 04:15 PM] (2) |
| Aug 1, 2017 | 8 | Docketing Statement for the Appellee Mylan Pharmaceuticals Inc.. Service: 08/01/2017 by email. [450752] [Robert Florence] [Entered: 08/01/2017 04:18 PM] (3) |
| Aug 1, 2017 | 9 | Certificate of Interest for the Appellee Mylan Pharmaceuticals Inc.. Service: 08/01/2017 by email. [450753] [Robert Florence] [Entered: 08/01/2017 04:19 PM] (2) |
| Aug 1, 2017 | 10 | Entry of appearance for Karen L. Carroll as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 08/01/2017 by email. [450755] [Karen Carroll] [Entered: 08/01/2017 04:23 PM] (2) |
| Aug 1, 2017 | 11 | Entry of appearance for Micheal L. Binns as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 08/01/2017 by email. [450756] [Micheal Binns] [Entered: 08/01/2017 04:26 PM] (2) |
| Aug 1, 2017 | 12 | Entry of appearance for Sharad K. Bijanki as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 08/01/2017 by email. [450757] [Sharad Bijanki] [Entered: 08/01/2017 04:29 PM] (2) |
| Aug 1, 2017 | 13 | Entry of appearance for Deepro R. Mukerjee as principal counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 08/01/2017 by email. [450763] [Deepro Mukerjee] [Entered: 08/01/2017 04:50 PM] (2) |
| Aug 1, 2017 | 14 | Entry of appearance for Lance A. Soderstrom as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 08/01/2017 by email. [450765] [Lance Soderstrom] [Entered: 08/01/2017 04:54 PM] (2) |
| Aug 1, 2017 | 15 | Entry of appearance for Zachary D. Silbersher as principal counsel for Appellees Flat Line Capital LLC and GeneriCo, LLC. Service: 08/01/2017 by email. [450769] [Zachary Silbersher] [Entered: 08/01/2017 05:08 PM] (2) |
| Aug 1, 2017 | 16 | Entry of appearance for Gaston Kroub as of counsel for Appellees Flat Line Capital LLC and GeneriCo, LLC. Service: 08/01/2017 by email. [450770] [Zachary Silbersher] [Entered: 08/01/2017 05:10 PM] (2) |
| Aug 1, 2017 | 17 | Certificate of Interest for the Appellees Flat Line Capital LLC and GeneriCo, LLC. Service: 08/01/2017 by email. [450771] [Zachary Silbersher] [Entered: 08/01/2017 05:11 PM] (2) |
| Aug 1, 2017 | 18 | Docketing Statement for the Appellees Flat Line Capital LLC and GeneriCo, LLC. Service: 08/01/2017 by email. [450772] [Zachary Silbersher] [Entered: 08/01/2017 05:12 PM] (0) |
| Jul 18, 2017 | 1 | Appeal docketed. Received: 07/18/2017. [447427] Entry of Appearance due 08/01/2017. Certificate of Interest due 08/01/2017. Docketing Statement due 08/01/2017. Certified List due 08/28/2017. [MJL] [Entered: 07/18/2017 03:08 PM] (63) |
